About karyopharm therapeutics inc - KPTI
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.
KPTI At a Glance
Karyopharm Therapeutics, Inc.
85 Wells Avenue
Newton, Massachusetts 02459-3298
| Phone | 1-617-658-0600 | Revenue | 146.07M | |
| Industry | Pharmaceuticals: Major | Net Income | -196,039,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 0.571% | |
| Fiscal Year-end | 12 / 2026 | Employees | 228 | |
| View SEC Filings |
KPTI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.551 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.769 |
| Enterprise Value to Sales | 1.714 |
| Total Debt to Enterprise Value | 0.933 |
KPTI Efficiency
| Revenue/Employee | 640,644.737 |
| Income Per Employee | -859,820.175 |
| Receivables Turnover | 5.58 |
| Total Asset Turnover | 1.036 |
KPTI Liquidity
| Current Ratio | 1.12 |
| Quick Ratio | 1.077 |
| Cash Ratio | 0.692 |
KPTI Profitability
| Gross Margin | 95.725 |
| Operating Margin | -62.10 |
| Pretax Margin | -134.182 |
| Net Margin | -134.212 |
| Return on Assets | -139.097 |
| Return on Equity | N/A |
| Return on Total Capital | 330.483 |
| Return on Invested Capital | N/A |
KPTI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -393.815 |
| Total Debt to Total Assets | 198.891 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -356.763 |